Search research articles
Contact Us
Filters
Showing results (221-230 of 349) with videos related to
Page
of 35
Sort By:
Circulation
|
December 23, 2009
Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial
Stuart J Pocock, Roxana Mehran, Tim C Clayton, et al.
European Heart Journal
|
March 17, 2012
Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?
Faiez Zannad, Wendy Gattis Stough, Stuart J Pocock, et al.
Journal of the American College of Cardiology
|
January 5, 2008
Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials
Stuart J Pocock, Alexandra J Lansky, Roxana Mehran, et al.
Journal of the American College of Cardiology
|
January 10, 2015
Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials
Gregg W Stone, Roxana Mehran, Patrick Goldstein, et al.
European Journal of Heart Failure
|
April 2, 2010
Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme
Nathaniel M Hawkins, Duolao Wang, Mark C Petrie, et al.
Circulation
|
July 20, 2007
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
Satish Kenchaiah, Stuart J Pocock, Duolao Wang, et al.
Journal of the American College of Cardiology
|
June 2, 2010
A risk score to predict bleeding in patients with acute coronary syndromes
Roxana Mehran, Stuart J Pocock, Eugenia Nikolsky, et al.
JACC. Cardiovascular Interventions
|
August 22, 2009
Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy
Roxana Mehran, Eugenia Nikolsky, Alexandra J Lansky, et al.
Journal of the American College of Cardiology
|
July 25, 2009
Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial
Abhiram Prasad, Bernard J Gersh, Michel E Bertrand, et al.
Lancet (London, England)
|
June 14, 2011
Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial
Gregg W Stone, Bernhard Witzenbichler, Giulio Guagliumi, et al.
Page
of 35
Search research articles
Search
Showing results (221-230 of 349) with videos related to
Sort By:
Page
of 35
Circulation
|
December 23, 2009
Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial
Stuart J Pocock, Roxana Mehran, Tim C Clayton, et al.
European Heart Journal
|
March 17, 2012
Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?
Faiez Zannad, Wendy Gattis Stough, Stuart J Pocock, et al.
Journal of the American College of Cardiology
|
January 5, 2008
Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials
Stuart J Pocock, Alexandra J Lansky, Roxana Mehran, et al.
Journal of the American College of Cardiology
|
January 10, 2015
Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials
Gregg W Stone, Roxana Mehran, Patrick Goldstein, et al.
European Journal of Heart Failure
|
April 2, 2010
Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme
Nathaniel M Hawkins, Duolao Wang, Mark C Petrie, et al.
Circulation
|
July 20, 2007
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
Satish Kenchaiah, Stuart J Pocock, Duolao Wang, et al.
Journal of the American College of Cardiology
|
June 2, 2010
A risk score to predict bleeding in patients with acute coronary syndromes
Roxana Mehran, Stuart J Pocock, Eugenia Nikolsky, et al.
JACC. Cardiovascular Interventions
|
August 22, 2009
Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy
Roxana Mehran, Eugenia Nikolsky, Alexandra J Lansky, et al.
Journal of the American College of Cardiology
|
July 25, 2009
Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial
Abhiram Prasad, Bernard J Gersh, Michel E Bertrand, et al.
Lancet (London, England)
|
June 14, 2011
Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial
Gregg W Stone, Bernhard Witzenbichler, Giulio Guagliumi, et al.
Page
of 35